chartexchange

IDEAYA Plans 90-Patient IDE849 NEC Cohort After FDA Meeting

Securities.io | Nov 16, 2026 6:06 PM EST

IDEAYA Biosciences announced on November 16, 2026 that it plans to enroll approximately 90 previously treated patients with gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) in a single-arm IDE849 extension cohort, following a Type C meeting with the U.S. Food and Drug Administration (FDA). The cohort is intended to support a potential accelerated-approval application for the investigational DLL3-targeting antibody-drug conjugate. The extension would sit within IDEAYA’s ongoing Phase…

Read original article